Abraham Rami Tzafriri

Dr. Abraham Rami Tzafriri

Research and Innovation, CBSET, Inc., Lexington, Massachusetts, USA
orcid

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2014 in JACC
Verified
Journal Article
Closed access
Abraham Rami TzafririAbraham Rami Tzafriri
Abraham Rami Tzafriri
FMFelix Mahfoud
Felix Mahfoud
JKJohn H. Keating
John H. Keating
PMPeter M. Markham
Peter M. Markham
ASAnna Spognardi
Anna Spognardi
Elazer R. EdelmanElazer R. Edelman
Elazer R. Edelman

1 August 2012 in Journal of Controlled Release
Verified
Journal Article
Open access
Abraham Rami TzafririAbraham Rami Tzafriri
Abraham Rami Tzafriri
AGAdam Groothuis
Adam Groothuis
GPG. Sylvester Price
G. Sylvester Price
Elazer R. EdelmanElazer R. Edelman
Elazer R. Edelman
Drug eluting stent designs abound and yet the dependence of efficacy on drug dose and elution duration remains unclear. We examined these issues within a mathematical framework of arterial drug distribution and receptor binding following stent elution. Model predictions that tissue content linearly tracks stent elution rate were validated in porcine coronary artery sirolimus-eluting stents implants. Arterial content varied for stent types, progressively declining from its Day 1 peak and tracking with rate-limiting drug elution--near zero-order release was three-fold more efficient at depositing drug in the stented lesion than near first-order release. In vivo data were consistent with an overabundance of non-specific sirolimus-binding sites relative to the specific receptors and to the delivered dose. The implication is that the persistence time of receptor saturation and effect is more sensitive to duration of elution than to eluted amount. Consequently, the eluted amount should be sufficiently high to saturate receptors at the target lesion, but dose escalation alone is an inefficient strategy for prolonging the duration of sirolimus deposition. Moreover, receptor saturating drug doses are predicted to be most efficacious when eluted from stents in a constant zero order fashion as this maximizes the duration of elution and receptor saturation.

1 September 2012 in Journal of Controlled Release
Verified
Journal Article
Open access
WCWenda C. Carlyle
Wenda C. Carlyle
JMJames B. McClain
James B. McClain
Abraham Rami TzafririAbraham Rami Tzafriri
Abraham Rami Tzafriri
LBLynn Bailey
Lynn Bailey
BZBrett G. Zani
Brett G. Zani
Elazer R. EdelmanElazer R. Edelman
Elazer R. Edelman
Current drug eluting stent (DES) technology is not optimized with regard to the pharmacokinetics of drug delivery. A novel, absorbable-coating sirolimus-eluting stent (AC-SES) was evaluated for its capacity to deliver drug more evenly within the intimal area rather than concentrating drug around the stent struts and for its ability to match coating erosion with drug release. The coating consisted of absorbable poly-lactide-co-glycolic acid (PLGA) and crystalline sirolimus deposited by a dry-powder electrostatic process. The AC-SES demonstrated enhanced drug stability under simulated use conditions and consistent drug delivery balanced with coating erosion in a porcine coronary implant model. The initial drug burst was eliminated and drug release was sustained after implantation. The coating was absorbed within 90 days. Following implantation into porcine coronary arteries the AC-SES coating is distributed in the surrounding intimal tissue over the course of several weeks. Computational modeling of drug delivery characteristics demonstrates how distributed coating optimizes the load of drug immediately around each stent strut and extends drug delivery between stent struts. The result was a highly efficient arterial uptake of drug with superior performance to a clinical bare metal stent (BMS). Neointimal thickness (0.17±0.07 mm vs. 0.28±0.11 mm) and area percent stenosis (22±9% vs. 35±12%) were significantly reduced (p<0.05) by the AC-SES compared to the BMS 30 days after stent implantation in an overlap configuration in porcine coronary arteries. Inflammation was significantly reduced in the AC-SES compared to the BMS at both 30 and 90 days after implantation. Biocompatible, rapidly absorbable stent coatings enable the matching of drug release with coating erosion and provide for the controlled migration of coating material into tissue to reduce vicissitudes in drug tissue levels, optimizing efficacy and reducing potential toxicity.

29 April 2015 in Science Translational Medicine
Verified
Journal Article
Closed access
PDF file
Abraham Rami TzafririAbraham Rami Tzafriri
Abraham Rami Tzafriri
JKJohn H. Keating
John H. Keating
PMPeter M. Markham
Peter M. Markham
ASAnna-Maria Spognardi
Anna-Maria Spognardi
JSJames R. L. Stanley
James R. L. Stanley
Elazer R. EdelmanElazer R. Edelman
Elazer R. Edelman
Local tissue anatomy determines the success of renal nerve ablation and explains its variable effects on blood pressure.

1 September 2019 in Journal of Controlled Release
Verified
Journal Article
Closed access
Abraham Rami TzafririAbraham Rami Tzafriri
Abraham Rami Tzafriri
SPSahil A. Parikh
Sahil A. Parikh
Elazer R. EdelmanElazer R. Edelman
Elazer R. Edelman

20 August 2020 in Biomaterials
Verified
Journal Article
Closed access
Abraham Rami TzafririAbraham Rami Tzafriri
Abraham Rami Tzafriri
BMBenny Muraj
Benny Muraj
FGFernando Garcia-Polite
Fernando Garcia-Polite
ASAntonio G. Salazar-Martín
Antonio G. Salazar-Martín
PMPeter Markham
Peter Markham
EEElazer R. Edelman
Elazer R. Edelman